Mayo scientists reverse fibrosis in preclinical studies

ROCHESTER, Minn. -- In cell and mouse models, Mayo Clinic researchers and collaborators have identified a way to slow and reverse the process of uncontrolled internal scarring, called fibrosis. This disease process has few effective therapies, no cure and can be fatal when it occurs in organs such as the liver (cirrhosis) or lungs (pulmonary [...]
Source: Mayo Clinic Minnesota News - Category: Hospital Management Source Type: news

Related Links:

Hepatic cirrhosis is a potential severe complication of chronic heart failure and has major implications on treatment options. In general, patients with cirrhosis are considered ineligible for isolated cardiac transplantation. Therefore, proper diagnosis of cirrhosis is paramount. The aim of this retrospective study is to explore the diagnostic value of abdominal ultrasound, hepatosplenic scan and abdominal computed tomography scan (CT scan) for liver disease secondary to advanced heart failure.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (564) Source Type: research
There are few data assessing factors and clinical outcomes in patients with liver cirrhosis for heart transplantation. The aim of this study was to compare the Model for End-Stage Liver Disease (MELD) score, the MELD-XI score and Child-Turcotte-Pugh (CTP) score risk prediction in cirrhotic patients undergoing heart transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (627) Source Type: research
Alcoholic liver disease (ALD) is the most prevalent type of chronic liver disease with significant morbidity and mortality worldwide. ALD begins with simple hepatic steatosis and progresses to alcoholic steatohepatitis, fibrosis, and cirrhosis. The severity of hepatic steatosis is highly associated with the development of later stages of ALD. This review explores the disturbances of alcohol-induced hepatic lipid metabolism through altered hepatic lipid uptake, de novo lipid synthesis, fatty acid oxidation, hepatic lipid export, and lipid droplet formation and catabolism. In addition, we review emerging data on the contribu...
Source: The Journal of Lipid Research - Category: Lipidology Authors: Tags: Reviews Source Type: research
It turns out that many more people than just boomers can benefit from testing for hepatitis C, a viral infection of the liver that often causes no symptoms. If you’re a member of the baby-boom generation (born between 1946 and 1964), your doctor may have already recommended the test. But those born before or after those years may not have known about the test unless they had a risk factor for hepatitis C, such as a history of intravenous drug use. A new guideline is changing this approach. Why the different recommendations for baby boomers? In 2012–2013, the CDC and the US Preventive Services Task Force (USPSTF...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Digestive Disorders Health Infectious diseases Men's Health Sexual Conditions Women's Health Source Type: blogs
We report a phase I pharmacological study of an oral formulation of CKD ‐516, a vascular‐disrupting agent, in patients with refractory solid tumors. Twenty‐seven patients (16 in the dose‐escalation cohort and 11 in the expansion cohort) received a single daily dose (5‐25 mg) of CKD‐516 five days per week. Nausea (67%) and diarrhea (63%) were the most common treatment‐related adverse events. The recommended phase II dose of oral CKD‐516 was 20 mg/d (15 mg/d with a body surface area (BSA)
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conclusion To improve public health, universal screening of pregnant women for HCV infection should be performed. Early identification of women and children with HCV infection is important to enable them to be included in assessment and/or treatment programs. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text
Source: American Journal of Perinatology Reports - Category: Perinatology & Neonatology Authors: Tags: Case Report Source Type: research
Direct-acting antiviral (DAA) HCV therapy is used in decompensated cirrhosis with the expectation of improvement in hepatic function. Little is known about the long-term benefit of successful treatment.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
An unexpected early increased incidence, recurrence and clinical aggressiveness of hepatocellular carcinoma (HCC) has been reported in HCV cirrhotic patients after treatment with direct-acting antivirals (DAA), but denied in other studies. To clarify this controversy, we performed a prospective multicenter study on consecutively enrolled cirrhotic patients with or without history of HCC undergoing DAA therapy.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Conditions:   HCC;   Cirrhosis, Liver Intervention:   Diagnostic Test: Breath Biopsy Sponsor:   University of Aberdeen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: At our institution, patients who were older or had significant co-morbid conditions (CAD, CHF, COPD, motility disorders, or cirrhosis) were more likely to have inadequate inpatient bowel preparation. Bowel preparation type did not affect the duration, quality of visualization, or successful cecal intubation. PMID: 32218419 [PubMed - as supplied by publisher]
Source: Minerva Gastroenterologica e Dietologica - Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
More News: Cirrhosis | Hospital Management | Liver | Study | Urology & Nephrology